儿童青少年单相抑郁使用抗抑郁药与躁狂发作风险
该队列研究基于瑞典2006至2019年全国住院和门诊数据,纳入4至17岁单相抑郁患者,比较诊断后90天内启用抗抑郁药组与未启用组。12周时两组躁狂/轻躁狂累积发病率差异无统计学意义,52周时治疗组风险略高。住院、父母双相障碍及使用抗精神病药和抗癫痫药是12周内躁狂/轻躁狂的最重要预测因素。
要点
- 12周时抗抑郁药组与对照组躁狂/轻躁狂累积发病率差异无统计学意义。
- 52周时治疗组累积发病率0.79%,对照组0.52%,风险差0.28%。
- 住院、父母双相障碍、使用抗精神病药和抗癫痫药是12周内重要预测因素。
核心结论
- 儿童青少年单相抑郁使用抗抑郁药在12周内未见治疗诱发性躁狂/轻躁狂的证据。
- 仅更长随访(52周)发现小幅风险差异。
- 某些患者特征与躁狂/轻躁狂相关,值得临床关注。
研究设计与样本
- 采用目标试验模拟框架的队列研究,评估瑞典2006年7月1日至2019年12月31日全国住院和门诊数据。
- 纳入4至17岁、诊断为抑郁但无既往躁狂/轻躁狂、双相障碍或精神病诊断且未使用心境稳定剂(锂盐、丙戊酸盐或卡马西平)处方的个体。
- 治疗组为诊断后90天内启用任何抗抑郁药的患者,对照组为90天内未启用抗抑郁药的患者。
- 随访至治疗开始后12周和52周,行政随访截至2020年12月31日。
主要发现
- 12周时共96例发生结局,52周时共291例发生结局。
- 12周时躁狂累积发病率治疗组为0.26%(95% CI,0.19%-0.33%),对照组为0.20%(95% CI,0.13%-0.27%),风险差0.06%(95% CI,-0.04%至0.16%)。
- 52周时累积发病率治疗组为0.79%(95% CI,0.68%-0.91%),对照组为0.52%(95% CI,0.40%-0.63%),风险差0.28%(95% CI,0.12%-0.44%)。
- 住院、父母双相障碍、使用抗精神病药和抗癫痫药是12周内躁狂/轻躁狂的最重要预测因素。
关键数值与推荐
- 主要结局为躁狂/轻躁狂诊断或启用心境稳定剂治疗。
- 采用Kaplan-Meier估计发病率,并使用逆概率治疗加权调整基线组间差异。
临床怎么用
- 儿童青少年单相抑郁启用抗抑郁药后12周内躁狂/轻躁狂风险未见显著增加,可在此时间框架内常规监测。
- 对具有住院、父母双相障碍、使用抗精神病药或抗癫痫药等特征的患者,应加强躁狂/轻躁狂的临床关注。
- 更长随访中观察到小幅风险差异,提示长期监测仍有必要。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Antidepressants are increasingly prescribed to pediatric patients with unipolar depression, but little is known about the risk of treatment-emergent mania. Previous research suggests pediatric patients may be particularly vulnerable to this adverse outcome. OBJECTIVE: To estimate whether pediatric patients treated with antidepressants have an increased incidence of mania/hypomania compared with patients not treated with antidepressants and to identify patient characteristics associated with the risk of mania/hypomania. DESIGN, SETTING, AND PARTICIPANTS: In a cohort study applying the target trial emulation framework, nationwide inpatient and outpatient care in Sweden from July 1, 2006, to December 31, 2019, was evaluated. Follow-up was conducted for 12 and 52 weeks after treatment initiation, with administrative follow-up ending December 31, 2020. Data were analyzed between May 1, 2022, and June 28, 2023. Individuals aged 4 to 17 years with a diagnosis of depression, but without a prior diagnosis of mania/hypomania, bipolar disorder, or psychosis or treatment with mood stabilizer (lithium, valproate, or carbamazepine), prescriptions were included. EXPOSURES: The treatment group included patients who initiated any antidepressant medication within 90 days of diagnosis. The control group included patients who did not initiate antidepressants within 90 days. MAIN OUTCOMES AND MEASURES: Diagnosis of mania/hypomania or initiation of mood stabilizer therapy. Incidences were estimated with Kaplan-Meier estimator, and inverse probability of treatment weighting was used to adjust for group differences at baseline. RESULTS: The cohort included 43 677 patients (28 885 [66%] girls); 24 573 in the treatment group and 19 104 in the control group. The median age was 15 (IQR, 14-16) years. The outcome occurred in 96 individuals by 12 weeks and in 291 by 52 weeks. The cumulative incidence of mania was 0.26% (95% CI, 0.19%-0.33%) in the treatment group and 0.20% (95% CI, 0.13%-0.27%) in the control group at 12 weeks, with a risk difference of 0.06% (95% CI, -0.04% to 0.16%). At 52 weeks, the cumulative incidence was 0.79% (95% CI, 0.68%-0.91%) in the treatment group and 0.52% (95% CI, 0.40%-0.63%) in the control group (risk difference, 0.28%; 95% CI, 0.12%-0.44%). Hospitalizations, parental bipolar disorder, and use of antipsychotics and antiepileptics were the most important predictors of mania/hypomania by 12 weeks. CONCLUSION: This cohort study found no evidence of treatment-emergent mania/hypomania by 12 weeks in children and adolescents. This corresponds to the time frame for antidepressants to exert their psychotropic effect. A small risk difference was found only with longer follow-up. Certain patient characteristics were associated with mania/hypomania, which warrants clinical attention.
引用
- Virtanen S, Lagerberg T, Takami Lageborn C, et al. Antidepressant Use and Risk of Manic Episodes in Children and Adolescents With Unipolar Depression. JAMA Psychiatry. 2024. PMID: 37755835. doi:10.1001/jamapsychiatry.2023.3555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。